Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

Blood

Volumn 123, Issue 12, 2014, Pages 1810-1817

  Woyach, Jennifer A ^a   Smucker, Kelly ^a   Smith, Lisa L ^a   Lozanski, Arletta ^a   Zhong, Yiming ^a   Ruppert, Amy S ^a   Lucas, David ^a   Williams, Katie ^a   Zhao, Weiqiang ^b   Rassenti, Laura ^c   Ghia, Emanuela ^c   Kipps, Thomas J ^d   Mantel, Rose ^a   Jones, Jeffrey ^a   Flynn, Joseph ^a   Maddocks, Kami ^a   O'Brien, Susan ^e   Furman, Richard R ^f   James, Danelle F ^g   Clow, Fong ^g   Lozanski, Gerard ^b   Johnson, Amy J ^a   Byrd, John C ^a   more..

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c CLL Research Consortium   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; BRUTON TYROSINE KINASE INHIBITOR; DASATINIB; DINACICLIB; DUVELISIB; IBRUTINIB; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70; SOTRASTAURIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; LYMPHOCYTE; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; RELAPSE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CD40 LIGAND; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; LYMPHOCYTOSIS; MALE; MIDDLE AGED; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84897069190     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527853     Document Type: Article

References (25)

1. Hallek M, Fischer K, Fingerle-Rowson G, et al International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
2. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49-53.
3. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-153.
4. Kath R, Blumenstengel K, Fricke HJ, Höffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol. 2001;127(1):48-54.
5. Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6-7):599-613. (Pubitemid 38824617)
6. Deglesne PA, Chevallier N, Letestu R, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res. 2006;66(14):7158-7166. (Pubitemid 44197694)
7. Bernal A, Pastore RD, Asgary Z, et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood. 2001;98(10):3050-3057.
8. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287- 6296.
9. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119(5):1182-1189.
10. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
11. Buchner M, Baer C, Prinz G, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115(22):4497-4506.
12. Furman RR, Byrd JC, Brown JR, et al. An isoform-selective inhibitor of phosphatidylinositol 3-kinase P110delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood. 2010;116(21). Abstract 55.
13. O'Brien S, Burger JA, Blum KA, et al. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Follow-up of a phase Ib/II study [abstract]. Blood. 2011;118(21). Abstract 983.
14. Ghia EM, Jain S, Widhopf GF II, et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008;111(10):5101-5108.
15. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood. 2003;102(3):1035-1041. (Pubitemid 36917801)
16. Langerak AW, Davi F, Ghia P, et al European Research Initiative on CLL (ERIC). Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. Leukemia. 2011;25(6):979-984.
17. Giudicelli V, Chaume D, Jabado-Michaloud J, Lefranc MP. Immunogenetics sequence annotation: the strategy of IMGT based on IMGTONTOLOGY. Stud Health Technol Inform. 2005;116:3-8.
18. Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol. 1991;147(5):1709-1719.
19. Claus R, Lucas DM, Stilgenbauer S, et al. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(20):2483-2491.
20. Herman SE, Farooqui M, Bezabhie R, Aue G, Wiestner A. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients [abstract].Blood. 2012;120(21). Abstract 185.
21. Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases [abstract]. J Clin Oncol. 2012(Suppl). Abstract 6508.
22. Burger JA, Keating MJ, Wierda WG, et al. The Btk inhibitor ibrutinib in combination with rituximab is well tolerated and has profound activitiy in high-risk chronic lymphocytic leuekmia (CLL) patients [abstract]. Blood. 2012;120(21). Abstract 187.
23. Muzio M, Apollonio B, Scielzo C, et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood. 2008;112(1):188-195.
24. Coelho V, Krysov S, Steele A, et al. Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. Blood. 2013;122(15):2664-2672.
25. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988.